Søren Østergaard

Title: The Innovative Contributions of Søren Østergaard

Introduction

Søren Østergaard is a notable inventor based in Brønshøj, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 2 patents, his work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents is focused on conjugated proteins with prolonged in vivo efficacy. This invention relates to blood coagulation factors and outlines processes for preparing these conjugated proteins. The method involves reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water-insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule. The resulting pharmaceutical compositions can be used in therapies, particularly for treating diseases alleviated by blood coagulation factors, such as hemophilia. Another significant patent involves anti-human interleukin-20 antibodies. These monoclonal antibodies can reduce IL20 mediated activation of receptor complexes in various species, including humans. The antibodies and their derivatives can be utilized for treating autoimmune or inflammatory diseases.

Career Highlights

Søren Østergaard has worked with prominent companies in the biotechnology sector, including Novo Nordisk A/S and Novo Nordisk Healthcare AG. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Throughout his career, Søren has collaborated with notable professionals in the field, including Jesper Pass and Jes Thorn Clausen. These collaborations have likely enhanced his research and development efforts.

Conclusion

Søren Østergaard's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.